Noile-Immune Biotech Inc.

Noile-Immune Biotech Inc. researches and develops CAR-T cells for novel cancer immunotherapies. Its pipeline includes NIB101, which targets solid tumor antigens; NIB102, a next-generation CAR-T cell therapy; NIB103, an autologous CAR-T cell therapy for mesothelin (MSLN); NIB104, a PRIME technology against solid tumor target antigens; ADAP01; AUTL01; and CHUG01. The company was incorporated in 2015 and is headquartered in Minato, Japan.